Explore /
Poster
/ A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.

A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.

Authors

Boyu Hu

Huntsman Cancer Institute, Salt Lake City, UT

Boyu Hu , Loretta J. Nastoupil , Houston Holmes , Ayad Hamdan , Abraham Kanate , Umar Farooq , Mohamad Cherry , Elizabeth Brem , Lauren C. Pinter-Brown , Daniel Arthur Ermann , Muhammad Husnain , Kenneth Micklethwaite , Syed Rizvi , Ashley Hammad , Ben Thompson , Enrique Zudaire , Socorro Portella , Mehdi Hamadani , James Essell , Susan Mary O'Brien

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT04637763

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7025)

DOI

10.1200/JCO.2024.42.16_suppl.7025

Abstract #

7025

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

$A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).$